



(11) **EP 3 461 847 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 30

(51) Int Cl.:
C07K 16/28 ^(2006.01) **A61K 39/395** ^(2006.01)
A61K 47/68 ^(2017.01) **A61P 35/00** ^(2006.01)

(48) Corrigendum issued on:
14.04.2021 Bulletin 2021/15

(43) Date of publication:
03.04.2019 Bulletin 2019/14

(21) Application number: **18204152.5**

(22) Date of filing: **06.12.2011**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **06.12.2010 US 42029110 P**
25.02.2011 US 201161446990 P

(60) Divisional application:
20189823.6 / 3 786 185

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
16200557.3 / 3 156 420
11847198.6 / 2 648 752

(71) Applicant: **Seagen Inc.**
Bothell, WA 98021 (US)

(72) Inventors:
• **SMITH, Maria Leia**
Seattle
WA 98133 (US)
• **SUSSMAN, Django**
Bothell, WA 98021 (US)
• **ARTHUR, William**
Bothell, WA 98021 (US)
• **NESTEROVA, Albina**
Bothell, WA 98021 (US)

(74) Representative: **J A Kemp LLP**
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

Remarks:

This application was filed on 02.11.2018 as a
divisional application to the application mentioned
under INID code 62.

(54) **HUMANIZED ANTIBODIES TO LIV-1 AND USE OF SAME TO TREAT CANCER**

(57) The invention provides humanized antibodies
that specifically bind to LIV-1. The antibodies are useful
for treatment and diagnoses of various cancers as well
as detecting LIV-1.

Activity of hLIV22 (HGLG) vcMMAE vs hLIV-14vcE




FIGURE 27

EP 3 461 847 A8